Maitreya Medica.

- Maitreya Medicare Limited is planning to expand its current hospital at Vesu, Surat, potentially adding 70 to 80 beds depending on specialty and services. - The upcoming Valsad unit has received building usage permission; hospital license is expected soon to start operations. - Equipment for Valsad unit is already ordered and being installed. - Expansion opportunities are being explored beyond Maharashtra and Gujarat. - Acquisition of Tulip Health has been made, focusing on preventive and rehabilitative care including elderly care and advanced diagnostics. - Future capex includes adding advanced tertiary and quaternary care services like organ transplants, robotic surgeries, and high-end radiotherapies to increase ARPOB. - Expansion plans are based on area need-based studies with typical bed size per hospital between 50 to 100 beds.

- Maitreya Medicare expects a 20%-25% year-on-year revenue growth in existing hospitals over the next 2-3 years. - Plans include increasing services and expanding bed capacity by 70 to 80 beds, depending on specialty and service design. - Expansion of the current Vesu, Surat unit and upcoming Valsad unit are part of growth strategy. - The company aims to introduce more advanced tertiary and quaternary care services like organ transplant, robotic surgeries, and high-end radiotherapies. - These high-end services are expected to significantly increase the Average Revenue Per Occupied Bed (ARPOB), targeting around Rs. 40,000. - Additional opportunities for capacity expansion are being explored as they arise.

- Expecting 20%-25% year-on-year revenue growth in existing hospitals driven by increased services and bed expansion (70 to 80 beds). - Future expansions planned with the upcoming Valsad unit and other opportunities to increase capacity. - ARPOB (Average Revenue Per Occupied Bed) projected to increase by at least 30%, aiming to reach around Rs. 40,000 with addition of advanced tertiary and quaternary care services like organ transplant and robotic surgeries. - Highest ever quarterly result recorded in Q3 FY24 with 34% year-on-year revenue growth. - PAT (Profit After Tax) positive at Rs. 1.57 crores with a 13% PAT margin, turning around from negative in the previous year. - EPS (Earnings Per Share) increased to 2.84 post bonus share issuance. - Sustained ARPOB growth expected due to introduction of advanced services and better revenue mix.

The transcript provided does not explicitly mention the current or expected order book or pending orders for Maitreya Medicare Limited. The discussion mainly revolves around: - Hospital bed size plans (typically 70 to 100 beds, sometimes 50 to 70 based on potential). - Expansion plans including the upcoming Valsad unit and possible further capacity increases. - Focus on increasing advanced tertiary and quaternary care services to boost Average Revenue Per Occupied Bed (ARPOB). - Revenue mix balancing between insurance schemes and out-of-pocket payments. - No direct references to order book or pending orders data. Therefore, there is no direct information on current or expected order book/pending orders in the transcript from the earnings call dated February 14, 2024.

- There is no specific mention of any current or upcoming fundraising through debt or equity in the provided transcript. - The company recently completed an IPO, which has boosted their business and helped fund growth. - Expansion plans include increasing bed capacity and new hospital units, such as the upcoming Valsad unit. - The company is focusing on internal growth, service enhancement, and acquisitions like Tulip Health. - No explicit statements were made regarding raising new debt or equity funds at this time.